Date and time: 30th October 2013, 10.30 – 16.05

Minutes: Final

Guideline Development Group Meeting 6 Type 2 Diabetes

Place: NICE Offices
Piccadilly Plaza
Manchester

Present: Damien Longson (Chair)
Natasha Jacques (NJ)
Anne Fittock (AF)
Ian Lewin (IL)
Sailesh Sankar (SS)
Maria Cowell (MC)
Jonathan Roddick (JR)
Yvonne Johns (YJ)
Natasha Marsland (NM)
Prunella Neale (PN)
Indranil Dasgupta (ID) – co-opted expert

Apologies: Amanda Adler (AA)

In attendance:

NICE Staff:

Abitha Senthinathan (AS)
Stephanie Mills (SM)
Mike Heath (MH)
Steven Ward (SWard)
Gabriel Rogers (GR)
Clifford Middleton (CM)

NICE Staff apologies:

Toni Tan (TT)
Jenny Kendrick (JK)

Observers:

Stacy Wilkinson – NICE Staff
Notes

1. DL welcomed the group to the sixth meeting of this GDG. Apologies were received from AA. The Chair asked ID to introduce himself to the group as he would be joining the GDG for a number of meetings as a co-opted expert. Prior to the start of the meeting MR had declared a number of conflicts to the NICE team. The Chair decision was for MR to leave the meeting and review participation in the rest of the development of the guideline. The rest of the group declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of this guideline beyond those which had previously been declared.

DL asked whether the group agreed that the minutes of the previous meeting were a clear and accurate record. The minutes were agreed by all with no amendments to be made. The GDG heard that the objectives of the meeting would be to take some important and challenging decisions about the technical approach to the synthesis that would eventually underpin recommendations on the pharmacological management of type 2 diabetes.

MH gave the GDG a brief update on joint working between the diabetes guidelines, supported by SS who had attended the diabetes oversight group meeting (DOG) held by NICE.

2. AS started the meeting by talking about the planned approached to the extraction and analysis of data for pharmacological management. The GDG were asked many questions about drug comparisons, outcomes, GRADE criteria for downgrading studies and how relevant data from older trials may be included. AS also gave a brief overview of the work that had been done so far looking at monotherapy.

3. SWard presented an update on modelling options for pharmacological management of type 2 diabetes remarking on the large amount of study literature within this area. SWard asked the GDG to think about the best studies and databases available for obtaining data which could be used as modelling inputs.

4. AS started the next session by asking the GDG if the same decisions applied to monotherapy would be applicable to the analysis for dual therapy and the GDG agreed. AS then went on to talk about the technical approach that could be taken towards analysing insulin. The GDG discussed what would be the most important answers for this synthesis to provide.

Once the GDG has finished their deliberations about insulin, the group provided guidance to AS on how they would like to see the results for the network meta-analyses going forward.

5. DL thanked the group for the hard work. SM reiterated the importance of the decisions made at the meeting. The group were reminded about all the dates left in the development of the guideline and were strongly encouraged to attend and also keep the team informed of any potential conflicts of interest.

Date, time and venue of the next meeting

Mon 16th & Tues 17th December 2013 – Red rooms, City Tower adjacent to NICE Offices, Manchester